Bicara Therapeutics’ (BCAX) “Outperform” Rating Reiterated at Wedbush

Wedbush reiterated their outperform rating on shares of Bicara Therapeutics (NASDAQ:BCAX) in a research note released on Thursday,RTT News reports. Wedbush currently has a $31.00 price target on the stock.

Other analysts have also recently issued research reports about the company. HC Wainwright upped their price objective on Bicara Therapeutics from $42.00 to $45.00 and gave the company a “buy” rating in a research report on Monday, January 27th. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $13.01 price target on shares of Bicara Therapeutics in a research report on Thursday, March 13th. Seven analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, Bicara Therapeutics has an average rating of “Buy” and an average price target of $36.50.

Bicara Therapeutics Stock Performance

Shares of Bicara Therapeutics stock opened at $13.40 on Thursday. Bicara Therapeutics has a 1 year low of $11.10 and a 1 year high of $28.09. The stock has a 50-day moving average price of $13.04.

Bicara Therapeutics (NASDAQ:BCAX) last issued its earnings results on Thursday, March 27th. The company reported ($0.39) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.31) by ($0.08). As a group, analysts expect that Bicara Therapeutics will post -2.59 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several hedge funds have recently bought and sold shares of the company. The Manufacturers Life Insurance Company purchased a new stake in shares of Bicara Therapeutics during the third quarter worth about $582,000. FMR LLC bought a new stake in Bicara Therapeutics in the 3rd quarter valued at $57,913,000. Walleye Capital LLC purchased a new stake in Bicara Therapeutics in the 3rd quarter worth $809,000. Vestal Point Capital LP bought a new position in shares of Bicara Therapeutics during the 3rd quarter valued at about $10,825,000. Finally, Braidwell LP bought a new stake in shares of Bicara Therapeutics in the third quarter worth about $42,219,000.

About Bicara Therapeutics

Bicara Therapeutics Inc, a clinical-stage biopharmaceutical company, develops bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines an epidermal growth factor receptor (EGFR) directed monoclonal antibody with a domain that binds to human transforming growth factor beta (TGF-b) for the treatment of solid tumors.